Senseonics launches Eversense 365 in Sweden, other countries to follow
By HME News Staff
Updated 12:32 PM CDT, Mon April 27, 2026
GERMANTOWN, Md. – Senseonics Holdings has launched its Eversense 365 CGM system in Europe, following CE Mark approval in January. The Eversense 365 is now available to the first patients in Sweden, with launches to follow in Germany, Spain, and Italy during the coming weeks.The next-generation Eversense 365 doubles sensor lifespan from the previously available Eversense E3, from six months to a full year, and delivers key improvements such as reducing the frequency of calibrations from once daily to once weekly. “This launch of Eversense 365 is a significant breakthrough for diabetes technology in Europe and for Senseonics as a business, as we successfully transition to an end-to-end commercial organization this year,” said Tim Goodnow, PhD, president and CEO. “Building on demonstrable commercial momentum in the U.S., European expansion is a key part of our Eversense 365 growth strategy, increasing our total addressable market by over 30 million patients.” The Eversense 365, billed as the world’s first and only one-year CGM, was approved by the U.S. Food and Drug Administration (FDA) in September of 2024 and launched in the country one month later.
Comments